Upstream Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UPB research report →
Range $25 – $25
Price Chart
About the company
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor.
- CEO
- E. Rand Sutherland
- IPO
- 2024
- Employees
- 75
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on UPB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $251.43M
- P/E
- -1.59
- PEG
- 0.05
- P/S
- 79.62
- P/B
- 0.93
- EV/EBITDA
- -1.11
- Div Yield
- 0.00%
- Gross Margin
- 98.45%
- Op Margin
- -5382.65%
- Net Margin
- -4955.67%
- ROE
- -48.40%
- ROIC
- -62.51%
Latest fiscal year · YoY change
- Revenue
- $2.85M+20.4%
- Gross Profit
- $2.85M+20.4%
- Op Income
- $-160,361,000
- Net Income
- $-143,443,000-128.4%
- EPS
- $-2.66-78.5%
- OCF Growth
- -125.2%
- FCF Growth
- -123.3%
- 52W High
- $33.68
- 52W Low
- $4.62
- 50D MA
- $6.22
- 200D MA
- $11.71
- Beta
- 1.39
- RSI (14)
- 26
- Avg Volume
- 601.86K
No earnings-call transcripts are available for UPB yet.
- Free Float
- 36.9%
- Shares Outstanding
- 54.42M
- Float Shares
- 20.08M
of shares held by institutions
145 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 8.16M | ▲ 61.33K |
| Orbimed Advisors LLC | 5.69M | 0 |
| Norges Bank | 3.77M | ▲ 3.77M |
| Blackrock, Inc. | 3.75M | ▲ 382.67K |
| Decheng Capital LLC | 2.72M | 0 |
| Enavate Sciences Gp, LLC | 2.46M | 0 |
| Vanguard Group Inc | 2.39M | ▼ 54.11K |
| Vanguard Capital Management LLC | 1.88M | ▲ 3.16K |
| Millennium Management LLC | 1.14M | ▲ 206.45K |
| D. E. Shaw & Co., Inc. | 1.04M | ▲ 215.56K |
| Jpmorgan Chase & Co | 1.01M | ▲ 549.04K |
| Qube Research & Technologies Ltd | 978.50K | ▲ 359.18K |
Held by 168 ETFs
Biggest fund positions in UPB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | GRAY MICHAEL | sell | 853 |
| Sep 16, 26 | Ambrose Allison | sell | 485 |
| Sep 16, 26 | Deykin Aaron | sell | 895 |
| Sep 16, 26 | Sutherland Everett Rand | sell | 2,095 |
| Sep 16, 26 | Houghton Adam | sell | 700 |
| Jun 16, 26 | GRAY MICHAEL | sell | 853 |
| Jun 16, 26 | Sutherland Everett Rand | sell | 2,095 |
| Jun 16, 26 | Houghton Adam | sell | 700 |
| Jun 16, 26 | Deykin Aaron | sell | 895 |
| Jun 16, 26 | Ambrose Allison | sell | 477 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our UPB coverage
Recent articles, reports, and earnings notes.
No research on UPB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UPB report →Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
defenseworld.net · Oct 5
These beaten-down stocks could bounce back in January, if history is any guide
marketwatch.com · Sep 21
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
globenewswire.com · Sep 8
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
globenewswire.com · Sep 1
Fannie Mae Announces Sale of Non-Performing Loans
gurufocus.com · Aug 19
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 11
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Jul 14
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction
gurufocus.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.